Summary • Stoke Therapeutics (STOK) rises 6.7% in pre-market trading to $32.50 amid investor interest.• Positive data on Zorevunersen presented at the 2025 AES Annual Meeting enhances investor ...
TipRanks on MSN
Biogen downgraded to reduce from hold at HSBC
HSBC downgraded Biogen (BIIB) to Reduce from Hold with a price target of $143, down from $144. The company’s “ailing” multiple sclerosis franchise ...
Analysts at Jefferies see blockbuster potential in zorevunersen in Dravet syndrome, with sales potentially reaching $1 ...
Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback